Losmapimod: meta-analysis of COVID-19 studies

All studies Serious outcomes Recovery RCTs All outcomes

Outcome (studies)

Improvement

Relative risk · 95% CI

All studies (1)−18%

RCTs (1)−18%

Late (1)−18%

00.511.5+

← Losmapimod
reduces riskIncreased
risk →

.hmva--anim-stagger .hmva__row{opacity:1}.hmva--anim .hmva__shade{opacity:var(--shade-opacity)}.hmva--anim-stagger .est .ci{transform:translateY(-50%)}.hmva--anim-stagger .est .pt{transform:translate(-50%,-50%)}.hmva--anim-stagger .hmva__bar{transform:none}.hmva--anim-settle .est .pt{left:calc(min(var(--pt), 1.5) / var(--max) * 100%)}.hmva--anim-settle .est .ci{left:calc(var(--lo) / var(--max) * 100%);width:calc((var(--hi) - var(--lo)) / var(--max) * 100%)}.hmva--anim-settle .hmva__bar--drug{width:calc(min(1, var(--rr)) * 100%)}.hmva--anim-settle .hmva__bar--control{width:calc(min(1, 1 / var(--rr)) * 100%)}

.fp--anim .fp__study,.fp--anim .fp__sum,.fp--anim .fp__het,.fp--anim .fp__dia,.fp--anim .fp__verdict,.fp--anim .fp__pooled{opacity:1}.fp--anim .fp__ci{transform:none}.fp--anim .fp__pt{transform:translate(-50%,-50%)}.fp--anim .fp__plot::before{opacity:var(--shade-opacity)}.fp--anim-settle .fp__pt{left:calc(min(var(--pt),var(--max))/var(--max)*100%)}.fp--anim-settle .fp__ci,.fp--anim-settle .fp__dia{left:calc(var(--lo)/var(--max)*100%);width:calc((var(--hi) - var(--lo))/var(--max)*100%)}

October 2026

Losmapimod COVID-19 studies

StudyImprovementRR · 95% CIOutcomeTreatmentControlRelative Risk

Ziegler (DB RCT)−18%1.18 · 0.79–1.76progression16/2216/26LOSVID

Late treatment−18%1.18 · 0.79–1.7616/2216/2618% higher risk

Tau² = 0.00, I² = 0.0%, p = 0.42

All studies−18%1.18 · 0.79–1.7616/2216/2618% higher risk

Tau² = 0.00, I² = 0.0%, p = 0.4200.511.52+

Rotate screen for more detailsIncrease width for more details

← Losmapimod
reduces riskLosmapimod
increases risk →

October 2026

Losmapimod COVID-19 serious outcomes

StudyImprovementRR · 95% CIOutcomeTreatmentControlRelative Risk

Ziegler (DB RCT)−18%1.18 · 0.79–1.76progression16/2216/26LOSVID

Late treatment−18%1.18 · 0.79–1.7616/2216/2618% higher risk

Tau² = 0.00, I² = 0.0%, p = 0.42

All studies−18%1.18 · 0.79–1.7616/2216/2618% higher risk

Tau² = 0.00, I² = 0.0%, p = 0.4200.511.52+

Rotate screen for more detailsIncrease width for more details

← Losmapimod
reduces riskLosmapimod
increases risk →

October 2026

Losmapimod COVID-19 recovery results

StudyImprovementRR · 95% CIOutcomeTreatmentControlRelative Risk

Ziegler (DB RCT)−14%1.14 · 0.67–1.95no recov.18 (n)24 (n)LOSVID

Late treatment−14%1.14 · 0.67–1.9518 (n)24 (n)14% higher risk

Tau² = 0.00, I² = 0.0%, p = 0.64

All studies−14%1.14 · 0.67–1.9518 (n)24 (n)14% higher risk

Tau² = 0.00, I² = 0.0%, p = 0.6400.511.52+

Rotate screen for more detailsIncrease width for more details

← Losmapimod
reduces riskLosmapimod
increases risk →

October 2026

Losmapimod COVID-19 Randomized Controlled Trials

StudyImprovementRR · 95% CIOutcomeTreatmentControlRelative Risk

Ziegler (DB RCT)−18%1.18 · 0.79–1.76progression16/2216/26LOSVID

Late treatment−18%1.18 · 0.79–1.7616/2216/2618% higher risk

Tau² = 0.00, I² = 0.0%, p = 0.42

All studies−18%1.18 · 0.79–1.7616/2216/2618% higher risk

Tau² = 0.00, I² = 0.0%, p = 0.4200.511.52+

Rotate screen for more detailsIncrease width for more details

← Losmapimod
reduces riskLosmapimod
increases risk →

October 2026

Losmapimod COVID-19 outcomes

StudyImprovementRR · 95% CIOutcomeTreatmentControlRelative Risk

Ziegler (DB RCT)−18%1.18 · 0.79–1.76progression16/2216/26LOSVID Ziegler (DB RCT)−14%1.14 · 0.67–1.95no recov.18 (n)24 (n)LOSVID Ziegler (DB RCT)−10%1.10 · 0.82–1.47no recov.22 (n)25 (n)LOSVID

00.511.52+

Rotate screen for more detailsIncrease width for more details

← Losmapimod
reduces riskLosmapimod
increases risk →